Impromune® Pasta

YOUR REFERENCE PRODUCT FOR THE IMMUNE SYSTEM (1)
What is it? What is it for?

IMPROMUNE® is a food supplement recommended for cats and dogs to strengthen their immune systems and to boost any innate or adaptive response (2).

Nucleoforce® is a specific Nucleotide formulation developed after studying the specific needs of different species of mammals. Nucleotides are semi-essential immunonutrients which, when taken orally, contribute to the correct development of the immune system.

Nucleoforce® regulates phagocytic activity of macrophages as well as the interaction between these and T lymphocytes. It also regulates the maturation, proliferation and activity of T lymphocytes. AHCC is an extract from the mycelium of Lentinus edodes, which regulates NK cell activity, as well as macrophage proliferation and differentiation of T to Th1 lymphocytes.

Different studies have shown that in combination, Nucleoforce® and AHCC have a synergic effect that acts on innate and adaptive responses.

This synergic effect has been patented.

Especially recommended for:

  • Puppies: immature immune systems, parvovirus, first vaccinations, etc.
  • Small breeds of dog and cats: bacterial infections, viruses, fungal infections and parasites (leishmania), immunosuppressant medication, etc.
    • After a prolonged stay at the vets (physiological stress)
    • Dogs and cats with gingivitis and/or other mouth problems
  • Older animals with immunosenescence and difficulty swallowing tablets

1, Informe petSellout March 2020.
2, Evangelio Sánchez E., Borda E., Tecles Vicente F., Martínez-Puig D., Cerón Madrigal J.J., Chetrit, C. 10th Congress of The European Society of Veterinary clinical Pathology, Barcelona, 2008.

Datasheet

Ingredients:

Each palatable tablet contains:

Nucleoforce® (Yeast extract S. cerevisiae

with Nucleotides)

585mg

AHCC (Lentinus edodes, mushroom)

315 mg

Magnesium stearate

 

 

Each ml of paste contains:

Nucleoforce® (Yeast extract S. cerevisiae

with Nucleotides)

14,62%

AHCC (Lentinus edodes, mushroom)

7,88%

 

Presentation:

In containers of 20 or 40 tablets, pouches of 200 tablets or a 30 ml syringe of palatable paste.

Each clinical package contains: 20 blister packs of 10 tablets or 12 dispenser sachets.

Storage conditions:

Store in a cool, dry place.

Recommended use (3,4,5):

Recommended for use in immunocompromised dogs and cats such as:

 

Use of IMPROMUNE®

Infectious processes:

• Bacteria (e.g. pyogenic infection), viruses (e.g. calicivirus, papillomatosis), Parasites (e.g.: demodicosis, giardia), fungal infections (e.g.: ringworm, Malassezia)

• Leishmania

 

 

Minimum duration 15-20 days

 

 

Minimum duration 6 months

 

Acquired immunosuppression:

• Administration of immunosuppressants (e.g. glucocorticoids)

• Chemotherapy

• Elderly animals, immunosenescence

• Stress:

Postoperative/post-multiple trauma conditions (e.g. Caesarean section, pyometra)

Reproduction (e.g. lactation, large litters) Puppies (e.g.: around vaccine period)

Malnutrition

 

Before and after treatment, 15-20 days

Before, during and after chemotherapy, 15-20 days

Minimum duration 30 days

 

 

Minimum duration 30 days

Minimum duration 30 days

Minimum duration 30 days

Posology and method of administration:

IMPROMUNE® is easy to administer because it is very palatable. The design of the tablets means they can be split to make it easier for smaller animals to ingest.

Depending on the situation, and the animal’s progress, the administration period can be extended at the veterinarian’s discretion.

IMPROMUNE® does not produce any adverse effects.

 

Weight of animal

Daily tablets

Daily dose

< 10 kg

½

2 ml

11 - 25 kg

1

4 ml

> 26 kg

2

8 ml

3, Romano V, Martínez-Puig D, Torre C, Iraculis N, Vilaseca LI, Chetrit C, Journal of Animal Physiology and Animal Nutrition Journal compilation, 2007.
4, Segarra S, Miró G, Montoya A, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis, Vet Parasitol, 2017;239:50-56.
5, Segarra S, Miró G, Montoya A, Pardo-Marín L, Teichenné J, Ferrer L, Cerón JJ, Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound, Parasit
Vectors. 2018 Feb 21;11(1):103.